Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Vanda Moves Ahead With Development Of Iloperidone, VEC-162

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Following an end-of-Phase II meeting with FDA, Vanda plans to initiate a Phase III study of VEC-162 in sleep disorders in third quarter.

You may also be interested in...



Vanda Reports Strong Phase III Data For Sleep Disorder Candidate In Chronic Insomnia

VEC-162 also being tested in transient insomnia, circadian rhythm sleep disorders and mood disorders.

Vanda Reports Strong Phase III Data For Sleep Disorder Candidate In Chronic Insomnia

VEC-162 also being tested in transient insomnia, circadian rhythm sleep disorders and mood disorders.

Vanda Atypical Antipsychotic Shows Apparent Genetic Response In Phase III

Study of iloperidone in schizophrenics meets its primary endpoint and also included a genetic profiling evaluation.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS066011

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By